Giles Kerr - Adaptimmune Therapeutics Independent Non-Executive Director
| ADAP Stock | USD 1.08 0.06 5.26% |
Director
Mr. Giles F. B. Kerr was appointed as Independent NonExecutive Director of the Company, effective from November 1, 2016. Mr. Kerr also serves as a member of the Audit Committee. Giles Kerr has substantial commercial and financial experience gained from service on numerous public and private company boards and as an audit partner. He has served as Director of Finance of the University of Oxford since 2005. He also currently serves as a Board member of public companies BTG plc, Paypoint plc and Senior plc as well as several private companies. Mr. Kerr previously served as Chief Financial Officer and a Board member of Amersham plc, until its acquisition by GE Healthcare in 2004, and as a director of Victrex plc and Elan Corporation Inc. Prior to his role at Amersham, he was a National Partner with Arthur Andersen. Mr. Kerr is an economics graduate of the University of York, U.K., and a Fellow of the Institute of Chartered Accountants of England and Wales. since 2016.
| Age | 56 |
| Tenure | 8 years |
| Address | 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX |
| Phone | 44 12 3543 0000 |
| Web | https://www.adaptimmune.com |
Adaptimmune Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2822) % which means that it has lost $0.2822 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8761) %, meaning that it created substantial loss on money invested by shareholders. Adaptimmune Therapeutics' management efficiency ratios could be used to measure how well Adaptimmune Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/24/2024, Return On Tangible Assets is likely to drop to -0.43. In addition to that, Return On Capital Employed is likely to drop to -0.69. As of 04/24/2024, Non Current Liabilities Total is likely to grow to about 178.8 M, while Total Current Liabilities is likely to drop slightly above 44.6 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Kaye FosterCheek | Agios Pharm | 58 | |
| Peter Moldt | Corvus Pharmaceuticals | 57 | |
| Bradley Thompson | Aptose Biosciences | N/A | |
| Deepa Pakianathan | Mereo BioPharma Group | 53 | |
| Denis Burger | Aptose Biosciences | 73 | |
| Erich Platzer | Aptose Biosciences | N/A | |
| Stewart Parker | Sangamo Therapeutics | 62 | |
| Maya Said | Pieris Pharmaceuticals | 40 | |
| Elisha Gould | Corvus Pharmaceuticals | 60 | |
| Denis Martineau | Aptose Biosciences | N/A | |
| Jacqualyn Fouse | Agios Pharm | 56 | |
| Robert Nelsen | Agios Pharm | 51 | |
| Scott Morrison | Corvus Pharmaceuticals | 60 | |
| Ian Clark | Agios Pharm | 57 | |
| Karen Smith | Sangamo Therapeutics | 50 | |
| Michael Wyzga | Mereo BioPharma Group | 63 | |
| Michael Richman | Pieris Pharmaceuticals | 53 | |
| Steven Prelack | Pieris Pharmaceuticals | 56 | |
| Steven Mento | Sangamo Therapeutics | 65 | |
| David Scadden | Agios Pharm | 65 | |
| Kunal Kashyap | Mereo BioPharma Group | 52 | |
Management Performance
| Return On Equity | -1.88 | ||||
| Return On Asset | -0.28 |
Adaptimmune Therapeutics Leadership Team
Elected by the shareholders, the Adaptimmune Therapeutics' board of directors comprises two types of representatives: Adaptimmune Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adaptimmune. The board's role is to monitor Adaptimmune Therapeutics' management team and ensure that shareholders' interests are well served. Adaptimmune Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adaptimmune Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ali Behbahani, Non-Executive Independent Director | ||
| Kerry Sharp, Senior Council | ||
| Sbastien Desprez, VP Affairs | ||
| Dana Lynch, Senior Communications | ||
| Bertrand Esq, Chief Officer | ||
| Adrian Rawcliffe, Principal CEO | ||
| Peter Thompson, Non-Executive Independent Director | ||
| Gwendolyn BinderScholl, CTO | ||
| Margaret Henry, Head Sec | ||
| Elliot Sigal, Non-Executive Independent Director | ||
| John Furey, Non-Executive Independent Director | ||
| ACA BA, Chief Officer | ||
| Paul Stead, Vice President - Business Development | ||
| Barbara Duncan, Independent Non-Executive Director | ||
| William Bertrand, COO | ||
| Tal Zaks, Independent Non-Executive Director | ||
| Rafael Amado, Chief Medical Officer | ||
| Sebastien Desprez, Vice President - Communications and Investor Relations | ||
| Lawrence Alleva, Non-Executive Independent Director | ||
| Helen TaytonMartin, COO | ||
| Giles Kerr, Independent Non-Executive Director | ||
| Helen MBA, CoFounder Officer | ||
| Jonathan Knowles, Non-Executive Chairman of the Board | ||
| Juli Miller, VP Relations | ||
| James Noble, CEO, Director | ||
| Charles Sigal, Non-Executive Independent Director | ||
| MD BA, Chief Officer | ||
| Cintia PharmD, Chief Officer | ||
| Ian Laing, Non-Executive Independent Director | ||
| John Lunger, Chief Patient Supply Officer | ||
| David Mott, Non-Executive Independent Director | ||
| William Roberts, Vice President of Investor Relations | ||
| BA ACA, Chief Officer | ||
| Joanna Brewer, Chief Officer |
Adaptimmune Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Adaptimmune Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.88 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (1.89) % | ||||
| Operating Margin | (215.83) % | ||||
| Current Valuation | 1.57 B | ||||
| Shares Outstanding | 255.56 M | ||||
| Shares Owned By Insiders | 0.38 % | ||||
| Shares Owned By Institutions | 67.52 % | ||||
| Number Of Shares Shorted | 3.2 M | ||||
| Price To Earning | (7.73) X |
Pair Trading with Adaptimmune Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptimmune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Adaptimmune Stock
| 0.66 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
The ability to find closely correlated positions to Adaptimmune Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptimmune Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptimmune Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptimmune Therapeutics Plc to buy it.
The correlation of Adaptimmune Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptimmune Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptimmune Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptimmune Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Adaptimmune Therapeutics information on this page should be used as a complementary analysis to other Adaptimmune Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Adaptimmune Stock analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is Adaptimmune Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptimmune Therapeutics. If investors know Adaptimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptimmune Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Revenue Per Share 0.3 | Quarterly Revenue Growth (0.98) | Return On Assets (0.28) | Return On Equity (1.88) |
The market value of Adaptimmune Therapeutics is measured differently than its book value, which is the value of Adaptimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptimmune Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Adaptimmune Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptimmune Therapeutics' market value can be influenced by many factors that don't directly affect Adaptimmune Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptimmune Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptimmune Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptimmune Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.